{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:19:57Z","timestamp":1793996397462,"version":"4.8.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001792","name":"James Cook University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001792","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Anesth"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Perioperative euglycaemic diabetic ketoacidosis (EuDKA) is a rare but life-threatening complication associated with sodium-glucose co-transporter-2 inhibitors (SGLT2i). It is characterised by ketonaemia, acidosis, and normal serum glucose. Whilst guidelines advise withholding SGLT2i prior to elective surgery, limited guidance exists for emergency procedures. This systematic review aimed to describe EuDKA cases following emergency surgery, identify patient characteristics, and examine contributing risk factors. A search of electronic databases up to April 2024 identified 30 cases from 21 publications. In most cases, EuDKA onset occurred within three days postoperatively (range: intraoperative to 10\u00a0days). Reported risk factors included inadequate SGLT2i withholding time, poor glycaemic control, morbid obesity, major surgery, intercurrent illness, suboptimal intraoperative diabetes management, and delayed gastrointestinal absorption. Morbidity was significant: ten patients required intensive care, two required intubation and ventilation, two received dialysis, and one underwent exploratory laparotomy. No deaths were reported. Due to atypical biochemical findings and non-specific symptoms, EuDKA remains under-recognised. Clinicians are advised to maintain a high index of suspicion, ensure appropriate perioperative insulin management, conduct vigilant laboratory monitoring, and provide patient education to reduce the risk in emergency surgical settings.<\/jats:p>","DOI":"10.1007\/s00540-025-03570-2","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T18:14:30Z","timestamp":1756664070000},"page":"976-988","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sodium glucose co-transporter 2 inhibitor-associated euglycaemic diabetic ketoacidosis in the emergency peri-operative period: a systematic review"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9709-7367","authenticated-orcid":false,"given":"Dennis","family":"Perez Castillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siva","family":"Senthuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sananta","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Heal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"key":"3570_CR1","unstructured":"Australian Institute of Health and Welfare. Diabetes: Australian Facts. Australian institute of health and welfare. Updated June 17, 2024. https:\/\/www.aihw.gov.au\/getmedia\/b1d366a5-edef-4356-98df-2ba74d5cb60c\/diabetes-australian-facts.pdf?v=20240617082657&inline=true. Accessed 19 July 2024"},{"key":"3570_CR2","unstructured":"National Prescribing Service. SGLT2 inhibitor listings: indications and combinations. RADAR. Published April 1, 2015. https:\/\/www.nps.org.au\/radar\/articles\/sglt2-inhibitor-listings-indications-and-combinations. Accessed 19 Jul 2024"},{"issue":"2","key":"3570_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/phar.1881","volume":"37","author":"KR Burke","year":"2017","unstructured":"Burke KR, Schumacher CA, Harpe SE. SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature. Pharmacotherapy. 2017;37(2):187\u201394. https:\/\/doi.org\/10.1002\/phar.1881.","journal-title":"Pharmacotherapy"},{"issue":"7","key":"3570_CR4","first-page":"451","volume":"40","author":"JF Mosley","year":"2015","unstructured":"Mosley JF, Smith L, Everton E, Fellner C. Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview. Pharm Ther. 2015;40(7):451\u201362.","journal-title":"Pharm Ther"},{"issue":"8","key":"3570_CR5","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/dom.12670","volume":"18","author":"F Zaccardi","year":"2016","unstructured":"Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18(8):783\u201394. https:\/\/doi.org\/10.1111\/dom.12670.","journal-title":"Diabetes Obes Metab"},{"key":"3570_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.31128\/AJGP-05-20-5432","volume":"50","author":"A Zala","year":"2021","unstructured":"Zala A, Maple-Brown L, Shaw J, Hare M. Current evidence and practical guidance for the use of sodium\u2013glucose co-transporter-2 inhibitors in type 2 diabetes. Aust J Gen Pract. 2021;50:225\u201330. https:\/\/doi.org\/10.31128\/AJGP-05-20-5432.","journal-title":"Aust J Gen Pract"},{"key":"3570_CR7","unstructured":"Australian Government Department of Health and Aged Care. Sodium glucose co-transporter 2 inhibitors: Safety advisor\u2014diabetic ketoacidosis and surgical procedures. Therapeutic Goods Administration. Published July 18, 2018. https:\/\/www.tga.gov.au\/news\/safety-alerts\/sodium-glucose-co-transporter-2-inhibitors. Accessed 19 Jul 2024"},{"key":"3570_CR8","unstructured":"National Prescribing Service. Dapagliflozin for chronic kidney disease. RADAR. Published September 1, 2022. https:\/\/www.nps.org.au\/radar\/articles\/dapagliflozin-for-chronic-kidney-disease. Accessed 19 Jul 2024"},{"issue":"2","key":"3570_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.5694\/mja2.50898","volume":"214","author":"PS Hamblin","year":"2021","unstructured":"Hamblin PS, Wong R, Bach LA. Sodium\u2013glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis. Med J Aust. 2021;214(2):94. https:\/\/doi.org\/10.5694\/mja2.50898.","journal-title":"Med J Aust"},{"issue":"9","key":"3570_CR10","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00228-023-03539-8","volume":"79","author":"J Lin","year":"2023","unstructured":"Lin J, Pearson S-A, Greenfield JR, Park KH, Havard A, Brieger D, Day RO, BFalster MO, Oliveira CJ. Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014\u20132022). Eur J Clin Pharmacol. 2023;79(9):1239\u201348. https:\/\/doi.org\/10.1007\/s00228-023-03539-8.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3570_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/dom.13012","volume":"20","author":"BM Bonora","year":"2018","unstructured":"Bonora BM, Avogaro A, Fadini GP. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: an updated review of the literature. Diabetes Obes Metab. 2018;20(1):25\u201333. https:\/\/doi.org\/10.1111\/dom.13012.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"3570_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2023-003666","volume":"11","author":"E Chow","year":"2023","unstructured":"Chow E, Clement S, Garg R. Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors. BMJ Open Diabetes Res Care. 2023;11(5): e003666. https:\/\/doi.org\/10.1136\/bmjdrc-2023-003666.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"3570_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bja.2019.03.028","volume":"123","author":"V Thiruvenkatarajan","year":"2019","unstructured":"Thiruvenkatarajan V, Meyer EJ, Nanjappa N, Van Wijk RM, Jesudason D. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review. Br J Anaesth. 2019;123(1):27\u201336. https:\/\/doi.org\/10.1016\/j.bja.2019.03.028.","journal-title":"Br J Anaesth"},{"issue":"23","key":"3570_CR14","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1056\/NEJMc1701990","volume":"376","author":"M Fralick","year":"2017","unstructured":"Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med. 2017;376(23):2300\u20132. https:\/\/doi.org\/10.1056\/NEJMc1701990.","journal-title":"N Engl J Med"},{"key":"3570_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4365","volume":"363","author":"P Ueda","year":"2018","unstructured":"Ueda P, Svanstr\u00f6m H, Melbye M, Eliasson B, Svensson A-M, Franz\u00e9n S, Gudbj\u00f6rnsdottir S, Hveem K, Jonasson C, Pasternak B. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363: k4365. https:\/\/doi.org\/10.1136\/bmj.k4365.","journal-title":"BMJ"},{"issue":"4","key":"3570_CR16","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.2337\/dc17-1721","volume":"41","author":"EJ Meyer","year":"2018","unstructured":"Meyer EJ, Gabb G, Jesudason D. SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and Australian spontaneous adverse event notifications. Diabetes Care. 2018;41(4):e47\u20139. https:\/\/doi.org\/10.2337\/dc17-1721.","journal-title":"Diabetes Care"},{"key":"3570_CR17","unstructured":"FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. US Food and Drug Administration. Published March 19, 2020. Updated March 15, 2022. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious. Accessed 19 Jul 2024"},{"key":"3570_CR18","unstructured":"ALERT UPDATE July 2022: Periprocedural Diabetic Ketoacidosis (DKA) with SGLT2 Inhibitor Use. Australian Diabetes Society. Published July 2022. https:\/\/www.diabetessociety.com.au\/downloads\/20220726%20ADS%20ADEA%20ANZCA%20NZSSD_DKA_SGLT2i_Alert_Ver%20July%202022.pdf. Accessed 19 Jul 2024"},{"issue":"11","key":"3570_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049592","volume":"11","author":"H Seki","year":"2021","unstructured":"Seki H, Kuratani N, Shiga T, Iwasaki Y, Karita K, Yasuda K, Yorosu T. Multicentre prospective observational study of sodium-glucose cotransporter-2 inhibitor-associated postoperative ketoacidosis: the SAPKA study protocol. BMJ Open. 2021;11(11): e049592. https:\/\/doi.org\/10.1136\/bmjopen-2021-049592.","journal-title":"BMJ Open"},{"key":"3570_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Chou R. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372: n160. https:\/\/doi.org\/10.1136\/bmj.n160.","journal-title":"BMJ"},{"issue":"11","key":"3570_CR21","first-page":"766","volume":"21","author":"N Abu-Amer","year":"2019","unstructured":"Abu-Amer N, Dinour D, Mini S, Beckerman P. An unusual case of metabolic acidosis: clinical case education. Isr Med Assoc J. 2019;21(11):766\u20138.","journal-title":"Isr Med Assoc J"},{"issue":"4","key":"3570_CR22","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.4496","volume":"11","author":"F Bteich","year":"2019","unstructured":"Bteich F, Daher G, Kapoor A, Charbek E, Kamel G. Post-surgical euglycemic diabetic ketoacidosis in a patient on empagliflozin in the intensive care unit. Cureus. 2019;11(4): e4496. https:\/\/doi.org\/10.7759\/cureus.4496.","journal-title":"Cureus"},{"issue":"6","key":"3570_CR23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15533","volume":"13","author":"HP Chandrakumar","year":"2021","unstructured":"Chandrakumar HP, Chillumuntala S, Singh G, McFarlane SI. Postoperative euglycemic ketoacidosis in type 2 diabetes associated with sodium-glucose cotransporter 2 inhibitor: insights into pathogenesis and management strategy. Cureus. 2021;13(6): e15533. https:\/\/doi.org\/10.7759\/cureus.15533.","journal-title":"Cureus"},{"issue":"21","key":"3570_CR24","first-page":"V02190125","volume":"181","author":"F Fisker","year":"2019","unstructured":"Fisker F, M\u00f8ller N, Lauritzen ES. Sodium-glucose-cotransporter 2 inhibitor-associated euglycaemic diabetic ketoacidosis. Ugeskr Laeger. 2019;181(21):V02190125.","journal-title":"Ugeskr Laeger"},{"issue":"12","key":"3570_CR25","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.33161","volume":"14","author":"J Fustiga","year":"2022","unstructured":"Fustiga J, Fernandes M, D\u00e2maso F, Duarte JA, Rodrigues C. Postop complication with euglycemic diabetic ketoacidosis in a patient receiving empagliflozin. Cureus. 2022;14(12): e33161. https:\/\/doi.org\/10.7759\/cureus.33161.","journal-title":"Cureus"},{"issue":"2","key":"3570_CR26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/icvts\/ivz091","volume":"29","author":"R Horikoshi","year":"2019","unstructured":"Horikoshi R, Kitamura T, Miyaji K. Ketoacidosis related to sodium glucose cotransporter 2 inhibitors after emergency coronary surgery. Interact Cardiovasc Thorac Surg. 2019;29(2):323\u20134. https:\/\/doi.org\/10.1093\/icvts\/ivz091.","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"3","key":"3570_CR27","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s10877-020-00518-7","volume":"35","author":"KC Hung","year":"2021","unstructured":"Hung KC, Chen JY, Chu CC, Sun CK. Perioperative surgical pleth index as a stress indicator for the prevention of perioperative euglycemic diabetic ketoacidosis. J Clin Monit Comput. 2021;35(3):673\u20134. https:\/\/doi.org\/10.1007\/s10877-020-00518-7.","journal-title":"J Clin Monit Comput"},{"issue":"1","key":"3570_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12055-021-01227-9","volume":"38","author":"T Ito","year":"2022","unstructured":"Ito T, Sugasawa G, Suzuki F, Sunada M, Iwamuro K, Nakano T, Saito M, Maeba S. Insulin and glucose infusion could prevent euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter 2 inhibitors. Indian J Thorac Cardiovasc Surg. 2022;38(1):87\u201391. https:\/\/doi.org\/10.1007\/s12055-021-01227-9.","journal-title":"Indian J Thorac Cardiovasc Surg"},{"issue":"8","key":"3570_CR29","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.5455","volume":"11","author":"U Jhaveri","year":"2019","unstructured":"Jhaveri U, Vardesh D. Sodium-glucose cotransporter-2 inhibitors and euglycaemic diabetic ketoacidosis in the perioperative period: case report. Cureus. 2019;11(8): e5455. https:\/\/doi.org\/10.7759\/cureus.5455.","journal-title":"Cureus"},{"issue":"4","key":"3570_CR30","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/jdi.13365","volume":"12","author":"C Kitahara","year":"2021","unstructured":"Kitahara C, Morita S, Kishimoto S, Matsuno S, Uraki S, Takeshima K, Furukawa Y, Inaba H, Iwakura H, Ariyasu H, Furuta H, Nishi M, Akamizu T. Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: a case report. J Diabetes Investig. 2021;12(4):664\u20137. https:\/\/doi.org\/10.1111\/jdi.13365.","journal-title":"J Diabetes Investig"},{"issue":"1","key":"3570_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.31403\/rpgo.v66i2235","volume":"66","author":"CG Le\u00f3n","year":"2020","unstructured":"Le\u00f3n CG, Ubierna JM, Zer\u00f3n HM. Post hysterectomy ketoacidosis due to empagliflozin. Rev Peru Ginecol Obstet. 2020;66(1):73\u20137. https:\/\/doi.org\/10.31403\/rpgo.v66i2235.","journal-title":"Rev Peru Ginecol Obstet"},{"key":"3570_CR32","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ijscr.2020.11.037","volume":"77","author":"PJ Lindsay","year":"2020","unstructured":"Lindsay PJ, Gibson LE, Bittner EA, Berg S, Chang MG. Sodium-glucose cotransporter-2 (SGLT2) inhibitor-induced euglycemic diabetic ketoacidosis complicating the perioperative management of a patient with type 2 diabetes mellitus (T2DM) and Fournier\u2019s gangrene: a case report. Int J Surg Case Rep. 2020;77:463\u20136. https:\/\/doi.org\/10.1016\/j.ijscr.2020.11.037.","journal-title":"Int J Surg Case Rep"},{"issue":"9","key":"3570_CR33","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.eprac.2022.06.006","volume":"28","author":"PB Mehta","year":"2022","unstructured":"Mehta PB, Robinson A, Burkhardt D, Rushakoff RJ. Inpatient perioperative euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter-2 inhibitors \u2013 lessons from a case series and strategies to decrease incidence. Endocr Pract. 2022;28(9):884\u20138. https:\/\/doi.org\/10.1016\/j.eprac.2022.06.006.","journal-title":"Endocr Pract"},{"issue":"1","key":"3570_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1136\/dtb.2023.250233rep","volume":"62","author":"DT Ritchie","year":"2023","unstructured":"Ritchie DT, Dixon J. SGLT2 inhibitor associated euglycaemic diabetic ketoacidosis in an orthopaedic trauma patient. Drug Ther Bull. 2023;62(1):11\u20135. https:\/\/doi.org\/10.1136\/dtb.2023.250233rep.","journal-title":"Drug Ther Bull"},{"issue":"2","key":"3570_CR35","doi-asserted-by":"publisher","first-page":"94","DOI":"10.11213\/tonyobyo.62.94","volume":"62","author":"Y Takemoto","year":"2019","unstructured":"Takemoto Y, Fujii K, Takata M, Nagata S, Hata SY, Yamamoto Y, Irie Y, Hazama Y, Yasuda T. A case of euglycemic diabetic ketoacidosis related with a sodium-glucose cotransporter 2 inhibitor after cholecystectomy for cholecystitis in a patient with type 2 diabetes. J Japan Diabetes Soc. 2019;62(2):94\u2013100. https:\/\/doi.org\/10.11213\/tonyobyo.62.94.","journal-title":"J Japan Diabetes Soc"},{"issue":"1","key":"3570_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.6314\/JIMT.201902_30(1).09","volume":"30","author":"MK Tsai","year":"2019","unstructured":"Tsai MK, Chen GL, Chuang TJ. Dapagliflozin-induced postoperative euglycemic diabetic ketoacidosis: two cases. J Intern Med Taiwan. 2019;30(1):47\u201350. https:\/\/doi.org\/10.6314\/JIMT.201902_30(1).09.","journal-title":"J Intern Med Taiwan"},{"key":"3570_CR37","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X16675259","volume":"4","author":"S Ullah","year":"2016","unstructured":"Ullah S, Khan N, Zeb H, Tahir H. Metabolic ketoacidosis with normal blood glucose: a rare complication of sodium-glucose cotransporter 2 inhibitors. SAGE Open Med Case Rep. 2016;4: 2050313x16675259. https:\/\/doi.org\/10.1177\/2050313X16675259.","journal-title":"SAGE Open Med Case Rep"},{"issue":"2","key":"3570_CR38","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.22229","volume":"14","author":"Q Wang","year":"2022","unstructured":"Wang Q, Wu K, Luo X, Dong X, Liu W, Tang Z, Zhang B. Dapagliflozin-associated euglycemic diabetic ketoacidosis presenting with severe abdominal pain mimicking acute peritonitis. Cureus. 2022;14(2): e22229. https:\/\/doi.org\/10.7759\/cureus.22229.","journal-title":"Cureus"},{"issue":"1","key":"3570_CR39","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.bja.2021.03.023","volume":"127","author":"R Wang","year":"2021","unstructured":"Wang R, Kave B, McIlroy E, Kyi M, Colman PG, Fourlanos S. Metabolic outcomes in patients with diabetes mellitus administered SGLT2 inhibitors immediately before emergency or elective surgery: single centre experience and recommendations. Br J Anaesth. 2021;127(1):e5\u20137. https:\/\/doi.org\/10.1016\/j.bja.2021.03.023.","journal-title":"Br J Anaesth"},{"issue":"16","key":"3570_CR40","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025590","volume":"100","author":"YC Wong","year":"2021","unstructured":"Wong YC, Liu KL, Lee CL. Postoperative extremity gangrene in a patient with type 2 diabetes taking SGLT2 inhibitors: a case report. Medicine (Baltimore). 2021;100(16): e25590. https:\/\/doi.org\/10.1097\/MD.0000000000025590.","journal-title":"Medicine (Baltimore)"},{"key":"3570_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-235953","author":"HL Yeoh","year":"2021","unstructured":"Yeoh HL, Lee M, Pan WJ, Ong HY. Case of sodium-glucose cotransporter-2 inhibitor-associated euglycaemic diabetic ketoacidosis. BMJ Case Rep. 2021. https:\/\/doi.org\/10.1136\/bcr-2020-235953.","journal-title":"BMJ Case Rep"},{"key":"3570_CR42","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/652341","volume":"2014","author":"AS Al-Mulhim","year":"2014","unstructured":"Al-Mulhim AS, Al-Hussaini HA, Al-Jalal BA, Al-Moagal RO, Al-Najjar SA. Obesity disease and surgery. Int J Chronic Dis. 2014;2014: 652341. https:\/\/doi.org\/10.1155\/2014\/652341.","journal-title":"Int J Chronic Dis"},{"issue":"Supplement_1","key":"3570_CR43","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.2337\/db18-2085-P","volume":"67","author":"A Elsheikh","year":"2018","unstructured":"Elsheikh A, Abdullah A, Wahab A, Eigbire GE, Salama A, Rajamani K. Impact of obesity on outcomes of diabetic ketoacidosis\u2014results from the national inpatient sample. Diabetes. 2018;67(Supplement_1):2085. https:\/\/doi.org\/10.2337\/db18-2085-P.","journal-title":"Diabetes"},{"key":"3570_CR44","unstructured":"Management of type 2 diabetes: A handbook for general practice. Royal Australian College of General Practitioners; July 2020. https:\/\/www.racgp.org.au\/getattachment\/41fee8dc-7f97-4f87-9d90-b7af337af778\/Management-of-type-2-diabetes-A-handbook-for-general-practice.aspx. Accessed 25 Jul 2024"},{"issue":"Supplement_1","key":"3570_CR45","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.2337\/dc17-S011","volume":"40","author":"American Diabetes Association","year":"2017","unstructured":"American Diabetes Association. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2017;40(Supplement_1):S64\u201374. https:\/\/doi.org\/10.2337\/dc17-S011.","journal-title":"Diabetes Care"},{"issue":"1","key":"3570_CR46","doi-asserted-by":"publisher","first-page":"39687","DOI":"10.1038\/srep39687","volume":"6","author":"B Zhu","year":"2016","unstructured":"Zhu B, Bu L, Zhang M, Gusdon AM, Zheng L, Rampersad S, Li J, Qu S. HbA1c as a screening tool for ketosis in patients with type 2 diabetes mellitus. Sci Rep. 2016;6(1):39687. https:\/\/doi.org\/10.1038\/srep39687.","journal-title":"Sci Rep"},{"issue":"1","key":"3570_CR47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00125-022-05815-1","volume":"66","author":"BC Lupsa","year":"2023","unstructured":"Lupsa BC, Kibbey RG, Inzucchi SE. Ketones: the double-edged sword of SGLT2 inhibitors? Diabetologia. 2023;66(1):23\u201332. https:\/\/doi.org\/10.1007\/s00125-022-05815-1.","journal-title":"Diabetologia"},{"issue":"1","key":"3570_CR48","doi-asserted-by":"publisher","first-page":"10293","DOI":"10.1038\/s41598-021-89752-w","volume":"11","author":"F Ata","year":"2021","unstructured":"Ata F, Yousaf Z, Khan AA, Razok A, Akram J, Ali EAH, Adbalhadi A, Ibrahim DA, Al Mohanadi DHSH, Danjuma MI. SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort. Sci Rep. 2021;11(1):10293. https:\/\/doi.org\/10.1038\/s41598-021-89752-w.","journal-title":"Sci Rep"},{"key":"3570_CR49","unstructured":"Australian Government Department of Health and Aged Care. Pharmaceutical benefits scheme (PBS) expenditure & prescriptions report 1 July 2022 to 30 June 2023. PBS analytical and strategics insight section; 2023. https:\/\/www.pbs.gov.au\/statistics\/expenditure-prescriptions\/2022-2023\/PBS-Expenditure-prescriptions-report-2022-23.pdf. Accessed 28 Jul 2024"},{"key":"3570_CR50","unstructured":"Jardiance\u00ae Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway. News Release. Boehringer Ingelheim. November 26, 2018. Accessed 28 Jul 2024. https:\/\/www.boehringer-ingelheim.com\/us\/jardiancer-recommended-preferred-sglt2-inhibitor-adults-type-2-diabetes-and-established"},{"key":"3570_CR51","unstructured":"Parker C. Old doc, new drugs: Glifozins. NewsGP. December 3, 2018.  https:\/\/www1.racgp.org.au\/newsgp\/clinical\/old-doc,-new-drug-glifozins. Accessed 28 July 2024"},{"issue":"9","key":"3570_CR52","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29652","volume":"14","author":"K Patel","year":"2022","unstructured":"Patel K, Nair A. A literature review of the therapeutic perspectives of sodium-glucose cotransporter-2 (SGLT2) inhibitor-induced euglycemic diabetic ketoacidosis. Cureus. 2022;14(9): e29652. https:\/\/doi.org\/10.7759\/cureus.29652.","journal-title":"Cureus"},{"issue":"4","key":"3570_CR53","first-page":"425","volume":"46","author":"H Tan","year":"2018","unstructured":"Tan H, Acharya S. Perioperative cessation of sodium-glucose cotransporter-2 inhibitors: 72 hours or seven days? Anaesth Intensive Care. 2018;46(4):425.","journal-title":"Anaesth Intensive Care"},{"issue":"4","key":"3570_CR54","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.bja.2023.06.063","volume":"131","author":"B Steinhorn","year":"2023","unstructured":"Steinhorn B, Wiener-Kronish J. Dose-dependent relationship between SGLT2 inhibitor hold time and risk for postoperative anion gap acidosis: a single-centre retrospective analysis. Br J Anaesth. 2023;131(4):682\u20136. https:\/\/doi.org\/10.1016\/j.bja.2023.06.063.","journal-title":"Br J Anaesth"},{"key":"3570_CR55","unstructured":"Clinical Guiding Principles for Sick Day Management of Adults with Type 1 Diabetes or Type 2 Diabetes: A Guide for Health Professionals. National Diabetes Services Scheme. June 2020. https:\/\/www.adea.com.au\/wp-content\/uploads\/2020\/09\/Sickdays-_12.pdf. Accessed 11 Jul 2024"},{"key":"3570_CR56","unstructured":"National Diabetes Services Scheme. Sick Day Management. National Diabetes Services Scheme. Published July 2020. https:\/\/www.ndss.com.au\/wp-content\/uploads\/aged-care-smit2-sick-day-management.pdf. Accessed 11 Jul 2024"},{"issue":"5","key":"3570_CR57","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1053\/j.ajkd.2022.10.012","volume":"81","author":"KE Watson","year":"2023","unstructured":"Watson KE, Dhaliwal K, Robertshaw S, Verdin N, Benterud E, Lamont N, Drall KM, McBrien K, Donald M, Tsuyuki RT, Campbell DJT, Pannu N, James MT. Consensus recommendations for sick day medication guidance for people with diabetes, kidney, or cardiovascular disease: a modified delphi process. Am J Kidney Dis. 2023;81(5):564\u201374. https:\/\/doi.org\/10.1053\/j.ajkd.2022.10.012.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"3570_CR58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4097\/kja.23158","volume":"77","author":"SK Oh","year":"2024","unstructured":"Oh SK, Won YJ, Lim BG. Surgical pleth index monitoring in perioperative pain management: usefulness and limitations. Korean J Anesthesiol. 2024;77(1):31\u201345. https:\/\/doi.org\/10.4097\/kja.23158.","journal-title":"Korean J Anesthesiol"},{"issue":"2","key":"3570_CR59","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.surg.2014.09.009","volume":"157","author":"DG Watt","year":"2015","unstructured":"Watt DG, Horgan PG, McMillan DC. Routine clinical markers of the magnitude of the systemic inflammatory response after elective operation: a systematic review. Surgery. 2015;157(2):362\u201380. https:\/\/doi.org\/10.1016\/j.surg.2014.09.009.","journal-title":"Surgery"},{"issue":"4","key":"3570_CR60","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1177\/0003134820956352","volume":"89","author":"DE McCabe","year":"2023","unstructured":"McCabe DE, Strollo BP, Fuhrman GM. Euglycemic diabetic ketoacidosis in the surgical patient. Am Surg. 2023;89(4):1083\u20136. https:\/\/doi.org\/10.1177\/0003134820956352.","journal-title":"Am Surg"},{"issue":"9","key":"3570_CR61","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.bjae.2020.04.006","volume":"20","author":"B Cusack","year":"2020","unstructured":"Cusack B, Buggy DJ. Anaesthesia, analgesia, and the surgical stress response. BJA Educ. 2020;20(9):321\u20138. https:\/\/doi.org\/10.1016\/j.bjae.2020.04.006.","journal-title":"BJA Educ"},{"issue":"8","key":"3570_CR62","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.4239\/wjd.v12.i8.1255","volume":"12","author":"U Galway","year":"2021","unstructured":"Galway U, Chahar P, Schmidt MT, Araujo-Duran JA, Shivakumar J, Turan A, Ruetzler K. Perioperative challenges in management of diabetic patients undergoing non-cardiac surgery. World J Diabetes. 2021;12(8):1255\u201366. https:\/\/doi.org\/10.4239\/wjd.v12.i8.1255.","journal-title":"World J Diabetes"},{"issue":"13","key":"3570_CR63","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006451","volume":"96","author":"X Li","year":"2017","unstructured":"Li X, Wang J, Chen K, Li Y, Wang H, Mu Y, Chen Y. Effect of different types of anesthesia on intraoperative blood glucose of diabetic patients: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2017;96(13): e6451. https:\/\/doi.org\/10.1097\/MD.0000000000006451.","journal-title":"Medicine (Baltimore)"},{"key":"3570_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-017-0258-5","author":"K Torimoto","year":"2017","unstructured":"Torimoto K, Okada Y, Koikawa K, Tanaka Y. Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring. Diabetol Metab Syndr. 2017. https:\/\/doi.org\/10.1186\/s13098-017-0258-5.","journal-title":"Diabetol Metab Syndr"},{"key":"3570_CR65","unstructured":"ALERT Severe Euglycaemic Ketoacidosis with SGLT2 Inhibitor Use in the Perioperative Period. Australian Diabetes Society. Published February 2018. https:\/\/www.diabetessociety.com.au\/documents\/2018_ALERT-ADS_SGLT2i_PerioperativeKetoacidosis_v3__final2018_02_14.pdf. Accessed 27 Jul 2025"},{"issue":"1","key":"3570_CR66","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jemermed.2017.10.001","volume":"54","author":"F Brown","year":"2018","unstructured":"Brown F, McColl T. Euglycemic diabetic ketoacidosis secondary to dapagliflozin use: a case report. J Emerg Med. 2018;54(1):109\u201311. https:\/\/doi.org\/10.1016\/j.jemermed.2017.10.001.","journal-title":"J Emerg Med"},{"issue":"2","key":"3570_CR67","doi-asserted-by":"publisher","DOI":"10.1177\/2324709617712736","volume":"5","author":"DA Kelmenson","year":"2017","unstructured":"Kelmenson DA, Burr K, Azhar Y, Reynolds P, Baker CA, Rasouli N. Euglycemic diabetic ketoacidosis with prolonged glucosuria associated with the sodium-glucose cotransporter-2 canagliflozin. J Invest Med High Impact Case Rep. 2017;5(2): 2324709617712736. https:\/\/doi.org\/10.1177\/2324709617712736.","journal-title":"J Invest Med High Impact Case Rep"}],"container-title":["Journal of Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00540-025-03570-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00540-025-03570-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00540-025-03570-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:07:35Z","timestamp":1764079655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00540-025-03570-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3570"],"URL":"https:\/\/doi.org\/10.1007\/s00540-025-03570-2","relation":{},"ISSN":["0913-8668","1438-8359"],"issn-type":[{"value":"0913-8668","type":"print"},{"value":"1438-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,31]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}